Several possible studies
Story checked
As weight-loss drug users turn to dietary supplements, doctors and regulators raise flags | Reuters (opens in a new tab)
reuters.com · 2026-10-20
Short answer
Several possible studiesStudy not confirmed.
Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
The story
As weight-loss drug users turn to dietary supplements, doctors and regulators raise flags | Reuters
reuters.com · 2026-10-20
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Multiple potential source studies identified.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
View article claimsSearch result
Several studies could fit.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
Evidence layer
Claim by claim
The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 4Not checkedGLP-1 drugs like Ozempic and Wegovy are widely used and have driven some users to seek dietary supplements because of side effects such as gastrointestinal distress, weakness, nausea, fatigue and constipation.View evidenceHide evidence
As statedsome 10 million Americans used them last year; could grow to 25 million by 2030
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 2 of 4Not checkedUS supplement sales have surged, with TikTok Shop generating more than $1 billion in dietary supplement sales in 2025, while nearly half of GLP-1 users reportedly started new vitamins and supplements after beginning the drugs.View evidenceHide evidence
As statedmore than $1 billion; nearly half
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 3 of 4Not checkedDoctors and researchers say supplements can be hard to evaluate because they do not need FDA preapproval, and some are calling for more regulation of online supplement marketing and ingredient oversight.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 4 of 4Not checkedCompanies and retailers are capitalizing on the GLP-1 supplement trend, with Target expanding offerings and The Vitamin Shoppe seeing double-digit sales growth in fiber and creatine.View evidenceHide evidence
As stateddouble-digit sales growth
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Method layer
Study not confirmed.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
PubMed, Europe PMC, Crossref · 15 candidate papers
Considerations for Dietary Supplements after GLP-1RA Treatment: A Narrative Review.
The Journal of Nutrition · 2026 · PubMed, Europe PMC
Review for "Real-world treatment trajectories preceding GLP-1 receptor agonist initiation in type 2 diabetes: A descriptive UK population-based cohort study on adherence to national clinical guidelines"
2026 · Crossref
Beyond Inflammation - A Multidisciplinary Approach to Managing Obesity and Cardiometabolic Risk in Inflammatory Bowel Disease.
2026 · Europe PMC
Dietary supplement considerations during glucagon-like Peptide-1 receptor agonist treatment: A narrative review.
Obesity Pillars · 2025 · PubMed, Europe PMC
Review for "Real-world treatment trajectories preceding GLP-1 receptor agonist initiation in type 2 diabetes: A descriptive UK population-based cohort study on adherence to national clinical guidelines"
2025 · Crossref